Contribute Try STAT+ Today

In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag placed on its newly approved Alzheimer’s treatment, a move that threatens to embroil the biotech company and its medication in yet another national controversy.

The patient advocacy group released a brief statement on Saturday calling the wholesale price “simply unacceptable” and that, for many people, it “will pose an insurmountable barrier to access … and may further deepen issues of health equity.” The organization expressed gratitude that the drug was approved in response to a “vast unmet need,” but called on Biogen to change the price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment